FDA proposes drug development guidance for rare pediatric diseases

(Reuters) – The U.S. Food and Drug Administration issued a draft guidance on Wednesday to simplify the procedure of developing drugs for rare pediatric disorders, such as Gaucher’s disease, by eliminating the need for certain trials and minimizing patient enrollment.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply